针对艾滋病病毒的初免-加强免疫策略。 - Suppr

Suppr

超能文献

Prime-boost immunization strategies against HIV.

作者信息

Barnett S W, Klinger J M, Doe B, Walker C M, Hansen L, Duliège A M, Sinangil F M

机构信息

Chiron Corporation, Emeryville, California 94608, USA.

出版信息

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S299-309.

PMID:9814958

Abstract

摘要

相似文献

Prime-boost immunization strategies against HIV.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S299-309.

HIV vaccines. Viral envelope fails to deliver?

Nature. 1998 Feb 12;391(6668):638-9. doi: 10.1038/35504.

DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.

Vaccine. 2006 Mar 20;24(13):2324-32. doi: 10.1016/j.vaccine.2005.11.063. Epub 2005 Dec 19.

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7. doi: 10.1097/01.qai.0000230318.40170.60.

Update on HIV vaccines.

STEP Perspect. 1997 Summer;9(2):5-6, 8-9.

Public health. A sound rationale needed for phase III HIV-1 vaccine trials.

Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620.

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.

Vaccine. 2005 Mar 31;23(19):2522-9. doi: 10.1016/j.vaccine.2004.10.028.

AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.

Science. 2004 Jun 25;304(5679):1913-4. doi: 10.1126/science.1100368.

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29.

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

J Infect Dis. 2004 Aug 15;190(4):702-6. doi: 10.1086/422258. Epub 2004 Jul 20.

引用本文的文献

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

J Virol. 2010 Jun;84(12):5975-85. doi: 10.1128/JVI.02533-09. Epub 2010 Apr 14.

Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.

Cancer Immunol Immunother. 2010 Mar;59(3):397-408. doi: 10.1007/s00262-009-0759-7. Epub 2009 Sep 16.

Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus.

J Virol. 2004 Jan;78(2):1020-5. doi: 10.1128/jvi.78.2.1020-1025.2004.

Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

J Virol. 2001 Aug;75(16):7435-52. doi: 10.1128/JVI.75.16.7435-7452.2001.

Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.

J Virol. 2001 May;75(9):4430-4. doi: 10.1128/JVI.75.9.4430-4434.2001.

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

J Virol. 2001 Feb;75(3):1547-50. doi: 10.1128/JVI.75.3.1547-1550.2001.

Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity.

J Virol. 1999 Nov;73(11):9485-95. doi: 10.1128/JVI.73.11.9485-9495.1999.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验